Spyre Therapeutics to Participate in Upcoming November Investor Conferences Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic...
Wednesday, October 30, 2024 BiopharmaWatch Research 1 min read
Key Takeaway: Spyre Therapeutics, Inc. (NASDAQ: SYRE) will participate in several upcoming investor conferences, showcasing its innovative approaches in biotechnology. The events include the Guggenheim's Inaugural Healthcare Innovation Conference on November 13, the Stifel 2024 Healthcare Conference on November 18, and the Jefferies London Healthcare Conference on November 20. Spyre intends to utilize these platforms to engage with investors and present their clinical-stage developments.
Price reaction · baseline $33.8 (2024-10-29 close) · hit after-hours · 1 other SYRE headline(s) in the window, move may be shared
day 0 close · peak
+1.1%
Market Sentiment Analysis
POSITIVE FACTORS
Participation in multiple upcoming investor conferences, indicating active engagement with the investment community.
Opportunity to showcase innovative antibody engineering and therapeutic potential.
Positive outlook on future funding and partnerships as a result of increased visibility.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+249%
120-day peak, hindsight
Typical move
3.2%
average across 3 past catalysts
Cash runway
~49 mo
Minimal dilution risk
Lead asset
Co-ArgI-PEG modified human arginase I
Phase 2 · Acute Myeloid Leukemia
Full Press Release Details
Event: Guggenheim's Inaugural Healthcare Innovation Conference Date: Wednesday, November 13, 2024 Time: 2:30pm ET
Event: Stifel 2024 Healthcare Conference Date: Monday, November 18, 2024 Time: 1:15 pm ET
Event: Jefferies London Healthcare Conference Date: Wednesday, November 20, 2024 Time: 10:30 am GMT